上海
*僅供醫學專業人士閱讀參考
*以下內容僅供醫療衛生專業人士瀏覽。
參考文獻
[1].GBD 2023 Breast Cancer Collaborators. Global, regional, and national burden of breast cancer among females, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Oncol. 2026;27(3):302-326.
[2].Zhou W, Ding Q. Advancing neoadjuvant therapy with inetetamab for HER2-Positive breast cancer. Cancer Lett. 2025;630:217852.
[3].Shang A, Xiong Y, Li M, et al. Focusing on the Advances and Challenges of HER2-Targeted Therapy: Cutting-Edge Breakthroughs in Neoadjuvant Treatment for HER2-Positive Breast Cancer. Technol Cancer Res Treat. 2026;25:15330338261446455.
[4].Yoon J, Oh DY. HER2-targeted therapies beyond breast cancer - an update. Nat Rev Clin Oncol. 2024;21(9):675-700. doi:10.1038/s41571-024-00924-9
[5].John Heymach, et al. Phase I BeamionLung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor, as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations: updated data. 2023 ASCO.
[6].Ichiki M, Wataya H, Yamada K, et al. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer. Onco Targets Ther. 2017;10:5107-5113. Published 2017 Oct 24.
[7].David Berz, et al. Zongertinib in HER2-altered breast cancer: preclinical activity and preliminary results from a Phase Ia dose-escalation study. 2025 ASCO.
[8].Sara Hurvitz, et al. Beamion BCGC-1: A Phase Ib/II dose escalation/optimization, randomized, open-label trial of oral zongertinib alone or in combination for advanced HER2-positive metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC).2025 ESMO.
[9].Shigehisa Kitano, et al. Zongertinib Combination Therapy in HER2-Positive Metastatic Breast Cancer (mBC): First Results From a Phase Ib/II Trial. 2026 ASCO.
[10].Kohei Shitara, et al. Beamion BCGC-1: Four new phase Ib/II cohorts to evaluate oral zongertinib with other agents in HER2-positive metastatic breast cancer (mBC) and metastatic colorectal cancer (mCRC). Abstract #: TPS3177
審批編號：SC-CN-19071
有效期至：2027年6月22日
僅供醫學專業人士交流使用
*此文僅用于向醫療衛生專業人士提供科學信息，不代表平臺立場。
特別聲明：以上內容(如有圖片或視頻亦包括在內)為自媒體平臺“網易號”用戶上傳并發布，本平臺僅提供信息存儲服務。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
